Abstract
Myelodysplastic syndromes (MDS) in children are associated with significant morbidity and risk of leukemic transformation. Allogeneic hematopoietic stem cell transplantation is the only curative therapy. The ideal allogeneic donor is an HLA-identical sibling or relative or Matched Related Donor (MRD). From 1990 to 2005, a total of 12 pediatric or young adult patients with MDS received bone marrow transplant from an HLA matched sibling at our institution. M:F ratio of the study group was 1.4; One patient belonged to ethnic minorities (8%); the median age at transplant was 13.4 years (range 1.1-20.6) and median weight was 54.7 kg (range 10.8-78).
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
